PubMed · 2647711
Ergoloid mesylates and ECT.
Abstract
Amnesia is the most common adverse effect among patients receiving electroconvulsive therapy. In a double-blind pilot study, patients receiving bilateral ECT were pretreated with ergoloid mesylates (N = 5) or placebo (N = 5). Consistent with the hypothesis that ergoloid mesylates might protect against ECT-associated amnesia, nonsignificant trends on some memory tests showed better performance for patients receiving active treatment. Unexpectedly, patients treated with ergoloid mesylates had a significantly better antidepressant response.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
G S Sachs, A J Gelenberg, B Bellinghausen, J Wojcik, W E Falk, A M Farhadi, M Jenike. 1989. Ergoloid mesylates and ECT.. https://pubmed.health/record/pubmed%3A2647711/ergoloid-mesylates-and-ect
Citations retain the original authors and DOI and include this site’s record URL. If this discovery service contributed to your research, you can also cite PubMed Health by Indiciae: BibTeX · RIS.